Loading...
ROCO
4105
Market cap598mUSD
Jul 09, Last price  
77.30TWD
1D
0.13%
1Q
3.76%
Jan 2017
-24.59%
IPO
17.84%
Name

TTY Biopharm Co Ltd

Chart & Performance

D1W1MN
ROCO:4105 chart
P/E
12.33
P/S
2.98
EPS
6.27
Div Yield, %
5.43%
Shrs. gr., 5y
1.16%
Rev. gr., 5y
8.86%
Revenues
6.45b
+9.49%
4,461,451,0004,221,836,0004,535,610,0005,061,606,0005,505,542,0005,893,847,0006,452,948,000
Net income
1.56b
+7.55%
900,081,000924,178,000831,894,0001,094,391,0001,128,509,0001,449,622,0001,559,125,000
CFO
1.76b
+30.57%
0526,351,0001,256,341,0001,235,759,0001,085,313,0001,349,376,0001,761,837,000
Dividend
Mar 27, 20254.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncology, Intensive Care, Healthcare, Export & CDMO, and an "Other" Business Unit. For anti-cancer and supportive therapies, the company markets a range of oncology medications under prominent brand names such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre. Addressing infectious diseases and influenza, TTY Biopharm supplies anti-infection drugs including Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax. Furthermore, the firm offers various healthcare-related pharmaceuticals designed for the digestive system, osteoporosis, and metabolic conditions, marketed under brands like Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin. Beyond pharmaceuticals, the company is also involved in distributing functional foods, conducting international trade (import/export), and engaging in investment ventures. Established in 1960, TTY Biopharm maintains its principal office in Taipei, Taiwan.
IPO date
Sep 27, 2001
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT